COLL - Collegium Pharmaceutical Inc Stock Price, Fair Value and News

36.07USD+0.65 (+1.84%)Market Closed

Market Summary

USD36.07+0.65

Market Closed

1.84%

COLL Stock Price

View Fullscreen

COLL RSI Chart

COLL Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

12.65

Price/Sales (Trailing)

2.08

EV/EBITDA

4.47

Price/Free Cashflow

3.83

COLL Price/Sales (Trailing)

COLL Profitability

EBT Margin

22.92%

Return on Equity

41.99%

Return on Assets

8.37%

Free Cashflow Yield

26.11%

COLL Fundamentals

COLL Revenue

Revenue (TTM)

566.9M

Rev. Growth (Yr)

0.11%

Rev. Growth (Qtr)

-3.22%

COLL Earnings

Earnings (TTM)

93.3M

Earnings Growth (Yr)

259.03%

Earnings Growth (Qtr)

-13.23%

Breaking Down COLL Revenue

Last 7 days

10.4%

Last 30 days

12.4%

Last 90 days

-2.7%

Trailing 12 Months

64.2%

How does COLL drawdown profile look like?

COLL Financial Health

Current Ratio

1.21

COLL Investor Care

Buy Backs (1Y)

5.43%

Diluted EPS (TTM)

2.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	566.9M	0	0	0
2023	524.9M	536.9M	546.6M	566.8M
2022	272.9M	313.5M	361.7M	463.9M
2021	321.2M	326.1M	325.8M	276.9M
2020	298.7M	301.7M	307.9M	310.0M
2019	291.2M	293.2M	295.9M	296.7M
2018	90.1M	159.6M	217.8M	280.4M
2017	7.5M	13.2M	19.0M	28.5M
2016	6.8M	5.1M	3.4M	1.7M
2015	0	0	10.2M	8.5M
2013	0	0	0	12.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

CEO	Mr. Joseph J. Ciaffoni
WEBSITE	collegiumpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	207

Collegium Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for Collegium Pharmaceutical Inc? What does COLL stand for in stocks?

COLL is the stock ticker symbol of Collegium Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Collegium Pharmaceutical Inc (COLL)?

As of Thu Jul 25 2024, market cap of Collegium Pharmaceutical Inc is 1.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers.

Is Collegium Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether COLL is over valued or under valued. Whether Collegium Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Collegium Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COLL.

What is Collegium Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, COLL's PE ratio (Price to Earnings) is 12.42 and Price to Sales (PS) ratio is 2.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COLL PE ratio will change depending on the future growth rate expectations of investors.